Observational Study on Subcutaneous FoslevodopaFoscarbidopa Infusion Effects on Sleep Problems in Adults with Advanced Parkinsons Disease

What this Trial Is About

Parkinsons disease PD is a neurological disorder that affects the brain, causing symptoms like tremors, stiffness, and slow movement. This research evaluates changes in sleep disturbances among adults with advanced Parkinsons disease who are receiving subcutaneous FoslevodopaFoscarbidopa as part of their routine care. The study includes about 103 adults across approximately 20 sites in Spain. Participants will receive subcutaneous infusion of FoslevodopaFoscarbidopa prescribed by their doctors according to local guidelines. The treatment is given as part of routine clinical practice without additional study procedures. The study follows participants for up to 12 weeks while they continue their prescribed therapy. During the study, participants will attend regular hospital or clinic visits as part of their usual care, with no extra burden from the trial. Researchers will assess changes in sleep disturbances using the Parkinsons Disease Sleep Scale - 2 PDSS-2 over approximately 12 weeks. The study focuses on observing outcomes without altering standard treatment and monitoring participants throughout this period.

A Study to Assess Change in Sleep Disturbances of Adult Participants With Advanced Parkinson's Disease Receiving Subcutaneous Foslevodopa/Foscarbidopa